Catasys, a provider of specialized health management services for health insurers and employers, reports that company CEO Omar Manejwala, M.D., will deliver a presentation at the American Society of Addiction Medicine’s (ASAM) 44th annual medical-scientific conference, “New Treatments in Addiction Medicine,” held April 25 – 28, 2013, in Chicago.
ASAM is a professional society representing more than 3,000 physicians focused on enhancing access and quality of addiction treatment, as well as educating physicians and the public and supporting research and prevention.
Dr. Manejwala, who oversees medical affairs at Catasys, will highlight innovation in clinical improvements in substance dependent populations in a presentation entitled “Combining Predictive Analytics, Outreach, Evidence Based Treatment, Case Management and Monitoring to Generate Clinical Outcome Driven Cost Reductions in High Cost Substance Dependent Populations.”
Catasys’ focus on substance dependence is based on its OnTrakTM program, which was designed to improve member health while lowering costs by combining evidence-based medical and psychosocial interventions with care coaching in a 52-week outpatient program.
On Friday, April 26, Dr. Manejwala will present Catasys’ research and OnTrack™ program to attendees of this year’s ASAM.
For further information visit www.catasyshealth.com or www.asam.org
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment